Medicalgorithmics Group specializes in AI-powered and noninvasive solutions for cardiac diagnostics
We have a clear goal: improving health through intelligent technologies.
Medicalgorithmics Group was established in 2005 and is headquartered in Warsaw, Poland. Over the past two decades, we have transformed into a global provider of cutting-edge solutions that help improve the health of patients around the world. Today, the Group operates globally through four businesses to address today and tomorrow’s healthcare needs.
Medicalgorithmics S.A.
Medicalgorithmics S.A. is a Warsaw-listed medical technology company, providing FDA certified AI-powered technology for cardiac arrhythmia diagnostics. It has achieved competitive stand-out by developing its unique algorithms, cutting-edge software and devices, enabling more precise diagnosis and personalized treatment than traditional technologies. Its ECG database with over 2.5 billion annotated heartbeats and a predictive analytics platform allow for recognition of heart disorders. Its flagship PocketECG monitors and diagnoses approx. 200,000 patients in over 20 countries annually.
Kardiolytics Inc.
This is a US-based subsidiary of Medicalgorithmics that specializes in the development and distribution of VCAST, innovative artificial intelligence-based algorithms for the analysis of cardiac imaging data.
Medicalgorithmics India
This is an Indian-based subsidiary of Medicalgorithmics responsible for the distribution of Medicalgorithmics products in India and the Asia-Pacific region. The company provides ECG analysis services for customers located in the Asia-Pacific region.
Medicalgorithmics Poland
This is a Polish-based subsidiary of Medicalgorithmics responsible for the distribution of Medicalgorithmics products in Poland. The company provides ECG analysis services for customers from North America, the European Union, Switzerland and the United Kingdom.
We have put science and innovation at the heart of our everyday efforts. Our FDA-approved software and devices help healthcare providers diagnose and manage arrhythmias more effectively than traditional technologies. Our ECG database with over 2.5 billion annotated heartbeats and a predictive analytics platform can help provide more accurate diagnosis and ultimately better patient outcomes.
Our innovative portfolio spans across software, artificial intelligence and cloud based solutions designed for healthcare systems, physicians and medical technology companies. Our flagship products include PocketECG system, FDA-approved TechBot and DeepRhythm software platforms for cardiac arrhythmia. We invented noninvasive AI-powered VCAST (Virtual Cardiac Stress Test) technology, which we believe can revolutionize the diagnosis and treatment of coronary artery disease in the years ahead.